NEXGEL, Inc.
NXGLHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. The company carries a $2.5M market cap, placing it firmly in the micro-cap category. It operates through two segments: Nexgel and CG labs.
Market Cap
$2.5M
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
-1.14
EPS (TTM)
$-15.30
EPS (Fwd)
$-4.40
ROE
-115.1%
ROA
-18.7%
Cash
$492,000
Total Debt
$7.5M
Free CF
$8.4M
52W Change
-90.3%
Annual Financials
Cash vs Debt
Where NXGL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NXGL finished 38.95% below its 150-day moving average ($9.50) and 58.21% below its 200-day moving average ($13.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NXGL overbought or oversold?
At the October 20, 2026 close, NXGL's RSI(14) was 73.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NEXGEL, Inc. carries $7.5M in total debt against $492K in cash reserves — debt is roughly 15.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $8.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -115.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.0M (2022) to $11.4M (2025), reflecting a 458% increase over the period.
NEXGEL, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing NXGL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.